Cancer Therapeutics Crc Pty Limited

Ctxt Pty Limited

Richard Charles Foitzik

Scott Raymond Walker

Michelle Ang Camerino

Danny Ganame

Ian Peter Holmes

Romina Lessene

Catherine Fae Hemley

Gillian Elizabeth Lunniss

Paul Anthony Stupple

Ylva Elisabet Bergman

Benjamin Joseph Morrow

H Rachel Lagiakos

Wilhelmus Johannes Antonius Kersten

Neil Choi

Marica Nikac

Andrew John Harvey

Ylva Elisabet Bergman Bozikis

John Feutrill

Helen Rachel Lagiakos

Yiva Bergman

Ylva Bergman

Jonathan Grant Hubert

Alexandra Elizabeth Stupple

Graeme Irvine Stevenson

Jo-Anne Pinson

Marcia Nikac

Neil Chol

George Nikolakopoulos

Gillian Elizabeth Lunnis

A compound of formula (I), or a pharmaceutical salt thereof:

Compounds

A compound of formula (I), or a pharmaceutically acceptable salt thereof.

A compound of formula (I) wherein: Ris optionally one or more halo or methyl groups; Rand Rare independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CHOH; Rand Rare independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CHOH; Rand Rare independently selected from H and Me; Ris either H or Me; Ris either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted Cheteroaryl. 

Tetrahydroisoquinoline derived PRMT5-inhibitors

A compound of formula I wherein: n is 1 or 2: p is 0 or 1; Ris optionally one or more halo or methyl groups; Rand Rare independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CHOH; Rand Rare independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CHOH; Rand Rare independently selected from H and Me; Ris either H or Me; Ris either H or Me; Rand Rare independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted Cheteroaryl. 

A compound of formula (1a), (1b) or (1c) wherein: n is 1 or 2; Ris H or Me; Ris optionally one or more halo or methyl groups; Rand Rare independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CHOH; Rand R(if present) are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CHOH; Rand Rare independently selected from H and Me; Ris selected from OH, &#x2014;NH, &#x2014;C(&#x2550;O)NH, and &#x2014;CHOH; Ris either H or Me; Ris either H or Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted Cheteroaryl. 

Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors

Substituted benzimidazole and 3H-imidazo[4,5-b]pyridines or formula I: where X and Y respectively are selected from: (i) N and N; and (ii) N and CR; Ais selected from: a Cheteroarylene group, containing 2 or 3 ring heteroatoms, where the bonds to L1 and the core are &#x3b2; to one another; Lis selected from: (i)&#x2014;O&#x2014;CH&#x2014;; (ii)&#x2014;CH&#x2014;O&#x2014;; (iii)&#x2014;C(&#x2550;O)&#x2014;NH&#x2014;; (iv)&#x2014;CH(OH)&#x2014;; (v)&#x2014;CH&#x2014;NH&#x2014;C(&#x2550;O)&#x2014;; (vi)&#x2014;S&#x2014;CH&#x2014;; (vii)&#x2014;CH&#x2014;S&#x2014;; (viii)&#x2014;CH&#x2014;; and (ix)&#x2014;CH(CH)&#x2014;O&#x2014;; A1 is phenyl, optionally substituted by F or CF; their use as pharmaceuticals, and in particular, in treating cancer and hemoglobinopathies. 

2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase

A compound of the formula (I): where Ror Ris a cyclic amine group and Ris an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.

FAK inhibitors

This invention relates to compounds of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.

VEGFR3 inhibitors

This invention relates to a compound of the formula (I):  The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.

A compound of the formula (I): where Ror Ris a cycle, amine group and Ris an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.

Selective FAK inhibitors

A compound of the formula (I): where Ror Ris a cyclc amine group and Ris an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.

Growing community of inventors

Parkville, Australia

Richard Charles Foitzik